RMD vs SPY: ResMed Inc. vs SPDR S&P 500 ETF Trust Historical Returns & Investment Comparison

This RMD vs SPY comparison analyzes the historical stock performance of ResMed Inc. and SPDR S&P 500 ETF Trust side-by-side. Using real, adjusted market data, this tool shows how identical investments in both stocks would have performed over time—highlighting differences in returns, volatility, and consistency across market cycles.

Use the interactive calculator below to adjust the investment amount and time period, visualizing how ResMed Inc. and SPDR S&P 500 ETF Trust have historically performed against each other.

Compare Stock Performance

Select two stocks and an investment amount to see how they compare over time.

Compare any two stocks to see which performed better historically

Performance Summary

$10,000 invested from 1995 to 2025 (31 years)

Head-to-Head Record

19
RMD Wins
0
Ties
12
SPY Wins

Over the 31-year comparison period, ResMed Inc. outperformed SPDR S&P 500 ETF Trust in 19 years, while SPDR S&P 500 ETF Trust outperformed ResMed Inc. in 12 years.

RMD - ResMed Inc.

Average Annual Return:+28.94%
Best Year:+224.11% (1998)
Worst Year:-42.48% (2002)
Win Rate:77.4% (24/31 years)
Total Value:$5,060,895.32
Total Gain:+$5,050,895.32 (+50508.95%)

SPY - SPDR S&P 500 ETF Trust

Average Annual Return:+11.71%
Best Year:+37.39% (1995)
Worst Year:-36.24% (2008)
Win Rate:81.8% (27/33 years)
Total Value:$250,597.02
Total Gain:+$240,597.02 (+2405.97%)

Overall Winner: RMD with an average annual return of 28.94% (vs 11.71% for SPY)

Understanding RMD vs SPY Performance

When comparing ResMed Inc. and SPDR S&P 500 ETF Trust, investors should consider multiple factors beyond just total returns. Volatility, consistency of growth, dividend payments, and sector-specific risks all play crucial roles in determining which stock might be better suited for your investment strategy and risk tolerance.

Historical performance data shows how each stock responded to market downturns, economic expansions, and company-specific events. While past performance doesn't guarantee future results, understanding these patterns can help inform investment decisions and portfolio allocation strategies.

Cumulative Growth Comparison

A $10,000 investment in ResMed Inc. grew to $5,060,895, compared to $250,597 for SPDR S&P 500 ETF Trust over the same period.

Year-by-Year Comparison

YearRMD ReturnRMD CumulativeSPY ReturnSPY CumulativeDifferenceWinner
1995 (Start)-$10,000.00-$10,000.00-Initial Investment
1996+20.93%$12,093.02+37.39%$15,035.16-16.46% (SPY)SPY
1997+83.33%$22,170.53+21.20%$18,223.19+62.13% (RMD)RMD
1998+30.81%$29,002.15+33.14%$24,261.81-2.32% (SPY)SPY
1999+224.11%$93,998.06+28.03%$31,063.11+196.07% (RMD)RMD
2000-2.34%$91,799.29+20.66%$37,482.18-23.00% (SPY)SPY
2001+95.11%$179,107.00-8.85%$34,165.23+103.96% (RMD)RMD
2002+36.94%$245,268.51-10.13%$30,703.75+47.07% (RMD)RMD
2003-42.48%$141,069.75-22.42%$23,820.14-20.06% (SPY)SPY
2004+33.78%$188,729.02+24.18%$29,580.86+9.60% (RMD)RMD
2005+21.67%$229,620.38+10.75%$32,760.13+10.92% (RMD)RMD
2006+50.80%$346,261.07+5.32%$34,504.59+45.47% (RMD)RMD
2007+28.78%$445,917.59+13.84%$39,281.03+14.94% (RMD)RMD
2008+4.91%$467,825.99+5.33%$41,375.53-0.42% (SPY)SPY
2009-26.95%$341,729.06-36.24%$26,382.38+9.28% (RMD)RMD
2010+36.19%$465,403.13+22.65%$32,359.23+13.54% (RMD)RMD
2011+31.24%$610,780.95+13.14%$36,610.39+18.10% (RMD)RMD
2012-27.47%$442,999.33+0.85%$36,922.44-28.32% (SPY)SPY
2013+63.74%$725,370.08+14.17%$42,154.69+49.57% (RMD)RMD
2014+12.77%$817,979.84+29.00%$54,380.19-16.23% (SPY)SPY
2015+23.95%$1,013,883.55+14.56%$62,298.86+9.39% (RMD)RMD
2016-4.18%$971,455.86+1.29%$63,101.60-5.47% (SPY)SPY
2017+21.35%$1,178,866.31+13.59%$71,674.43+7.76% (RMD)RMD
2018+39.28%$1,641,946.10+20.78%$86,569.38+18.50% (RMD)RMD
2019+35.04%$2,217,320.48-5.25%$82,026.91+40.29% (RMD)RMD
2020+40.44%$3,113,915.40+31.09%$107,527.02+9.35% (RMD)RMD
2021+37.32%$4,276,019.12+17.24%$126,059.55+20.08% (RMD)RMD
2022+23.63%$5,286,539.62+30.51%$164,514.60-6.87% (SPY)SPY
2023-19.17%$4,273,176.59-18.65%$133,838.54-0.52% (SPY)SPY
2024-16.94%$3,549,463.57+26.71%$169,585.78-43.65% (SPY)SPY
2025+34.37%$4,769,494.66+25.59%$212,981.61+8.78% (RMD)RMD
2026+6.11%$5,060,895.32+17.66%$250,597.02-11.55% (SPY)SPY

Annual returns include dividends and stock splits. Cumulative values show growth of $10,000 invested from the first year. Positive difference means RMD outperformed SPY that year.

Company Profiles

1

ResMed Inc.

RMD

ResMed is a global leader in digital health and cloud-connected medical devices. It specializes in products for the treatment of sleep apnea, COPD, and other respiratory conditions.

Key Innovations

  • CPAP technology advancements
  • AirSense connected devices
  • MyAir patient engagement app

Business Segments

  • Sleep and Respiratory Care
    Devices and masks for sleep apnea and ventilation.
  • SaaS
    Software for out-of-hospital care providers.
2

SPDR S&P 500 ETF Trust

SPY

SPY is the first exchange-traded fund (ETF) listed in the US. It is designed to track the S&P 500 Index, which measures the performance of the large-cap segment of the US equity market.

Key Innovations

  • First US-listed ETF

Business Segments

  • ETF
    Passive investment vehicle tracking the S&P 500.

How This Comparison Works

Our stock comparison tool uses adjusted closing prices to calculate year-by-year returns for both stocks. This ensures an apples-to-apples comparison that accounts for:

  • Dividends: All dividend payments are reinvested
  • Stock splits: Historical prices are adjusted for all splits
  • Head-to-head record: Shows which stock outperformed each year
  • Statistical analysis: Average returns, best/worst years, and win rates

Share This Comparison

Important Disclaimer

This comparison tool is for educational and informational purposes only and does not constitute financial, investment, or trading advice. Past performance is not indicative of future results. Historical returns include dividends and stock splits but do not account for taxes, fees, inflation, or individual circumstances. Stock market investments carry risk, including the potential loss of principal. Always consult with a qualified financial advisor before making investment decisions. The data presented is based on historical market data and may contain inaccuracies or delays.